BASEL, Switzerland, and DARMSTADT, Germany - 14 February 2007 - Nitec Pharma, a specialist pharmaceutical company focused on the treatment of chronic inflammatory diseases, announced today that it has granted marketing rights in Germany to Merck Pharma GmbH, a division of Merck KGaA, for Lodotra, a modified-release tablet that has been developed to optimize the efficacy of orally administered low-dose prednisone in Rheumatoid Arthritis (RA). Terms of the deal were not disclosed.
